Results 171 to 180 of about 1,261,156 (366)

Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Identifying functional measures that are both valid and reliable in the limb girdle muscular dystrophy (LGMD) population is critical for quantifying the level of functional impairment related to disease progression in order to establish clinical trial readiness in the context of anticipated therapeutic trials.
Stephanie M. Hunn, Lindsay N. Alfano, Aileen Jones, Amanda Butler, Linda P. Lowes, Megan A. Iammarino, Natalie F. Reash, Lindsay Pietruszewski, Sandhya Sasidharan, Melissa Currence, Jeffrey M. Statland, Talia Strahler, Robert Will, Matthew Wicklund, Stacy Dixon, Renee Augsburger, Tahseen Mozaffar, Katie M. Laubscher, Shelley R. H. Mockler, Katherine D. Mathews, Nikia Stinson, Doris G. Leung, Molly M. Stark, Rebecca A. Horton, Peter B. Kang, Meredith K. James, Amanda Clause, Conrad C. Weihl, Nicholas E. Johnson, GRASP‐LGMD Consortium   +29 more
wiley   +1 more source

Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events [PDF]

, 2015
Mitsuhiro Nakamura, Ryogo Umetsu, Junko Abe, Toshinobu Matsui, Natsumi Ueda, Yamato Kato, Sayaka Sasaoka, Kohei Tahara, Hirofumi Takeuchi, Yasutomi Kinosada   +9 more
openalex   +1 more source

Very High‐Frequency Oscillations in Mesial Temporal Lobe Epilepsy: Identifying the Epileptogenic Zone

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate the reliability of very high‐frequency oscillations (VHFOs, 500–2000 Hz) as biomarkers in identifying the epileptogenic zone (EZ) in mesial temporal lobe epilepsy (MTLE) patients. Methods We reviewed 19 MTLE patients who underwent stereo‐electroencephalography‐guided radiofrequency thermocoagulation.
Stéphane Jean, Yihai Dai, Yan Cui, Donghuo Deng, Zhe Qian, Panashe Tevin Tagu, Weitao Chen, Weihong Liu, Xiaoqiang Wei, Xinrong Fang, Shiwei Song   +10 more
wiley   +1 more source

Chorioamnionitis following vaccination in the Vaccine Adverse Event Reporting System [PDF]

, 2015
Hema Datwani, Pedro L. Moro, Theresa Harrington, Karen R. Broder   +3 more
openalex   +1 more source

Introduction of Electronic Adverse Event Reporting System [PDF]

Journal of Korean Society for Clinical Pharmacology and Therapeutics, 2004
OkGu Kim, Byung Joo Park
openaire   +1 more source

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib, Kristl G. Claeys, Vera Bril, Yessar Hussain, Kelly Gwathmey, Gregory Sahagian, Elena Cortés‐Vicente, Edward Brauer, Deborah Gelinas, Anne Sumbul, Rosa H. Jimenez, Daniela Hristova, Delphine Masschaele, Renato Mantegazza, Andreas Meisel, Shahram Attarian, On behalf of the ADAPT NXT Study Group   +16 more
wiley   +1 more source

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system

Frontiers in Pharmacology
ObjectiveThis study aimed to explore the neurological adverse events of oxaliplatin through the Food and Drug Administration Adverse Event Reporting System (FAERS) database and to provide reference for safe clinical drug use.MethodsThe adverse events ...
Xianglin Pan, Xiangtian Xiao, Yiling Ding, Yamin Shu, Wenting Zhang, Liu Huang   +5 more
doaj   +1 more source

Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [PDF]

, 2016
Antonia V. Bennett, Amylou C. Dueck, Sandra A. Mitchell, Tito R. Mendoza, Bryce B. Reeve, Thomas M. Atkinson, Kathleen M. Castro, Andrea Denicoff, Lauren J. Rogak, Jay K. Harness, James D. Bearden, Donna Bryant, Robert D. Siegel, Deborah Schrag, Ethan Basch   +14 more
openalex   +1 more source

Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial

Arthritis Care &Research, EarlyView.
Objective This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods In an open‐label, phase 1 study (SELECT‐YOUTH), enrolled patients, aged 2 to <18 years with pcJIA, received body weight–based ...
Hermine I. Brunner, Anna Shmagel, Gerd Horneff, Ivan Foeldvari, Jordi Antón, Athimalaipet V. Ramanan, Yuli Qian, Kristina Unnebrink, Shuai Hao, Heidi S. Camp, Nasser Khan, Wei Liu, Mohamed‐Eslam F. Mohamed   +12 more
wiley   +1 more source

Pregnancy Outcomes of Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review

Arthritis Care &Research, EarlyView.
Objective Targeted synthetic disease‐modifying antirheumatic drugs (tsDMARDs) have expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their effects on pregnancy.
Vienna Cheng, Neda Amiri, Vicki Cheng, Ursula Ellis, Jacquelyn J. Cragg, Mark Harrison, Laurie Proulx, Mary A. De Vera   +7 more
wiley   +1 more source